The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes
Open accessAbstract
The pathology of psoriasis strongly depends on IL-17A. Monoclonal antibodies blocking either the cytokine or its receptor are among the most efficient treatments for psoriatic patients. Keratinocytes can be activated upon exposure to IL-17A and tumor necrosis factor-α and secrete secondary cytokines and chemokines in the inflamed skin. In psoriasis and its imiquimod-induced mouse model, a strong skin infiltration of neutrophils and inflammatory monocytes can be observed. However, to date, it is not clear how exactly those cellular populations are attracted to the skin and how they contribute to the pathogenesis of the disease. To define the crucial cell type responding to IL-17 and initiating the downstream pathology in psoriasis-like dermatitis, we used mice specifically lacking the IL-17 receptor (IL-17RA) in different cell types. Deletion of IL-17RA in T cells or myeloid had no impact on disease development. Only deletion of this receptor in keratinocytes reflected the full-body deletion of IL-17RA, resulting in strongly reduced dermatitis development. Imiquimod treatment of those IL-17 signaling-deficient mice maintained high monocytic infiltration but failed to attract neutrophils into the skin. We conclude that keratinocytes are a critical cellular target for IL-17A-mediated neutrophil attraction and psoriasis development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 1×
“However, in contrast to psoriasis patients treated with IL-17 pathwayeneutralizing drugs, who often show a complete remission (Langley et al., 2014; Papp et al., 2012; Waisman, 2012), mice deficient for IL-17RA are not fully resistant to disease development but show residual disease scores (El Malki et al.”
ResultPlasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Ishigame, H., Kakuta, S., Nagai, T., Kadoki, M., Nambu, A., Komiyama, Y., Fujikado, N., Tanahashi, Y., Akitsu, A., Kotaki, H., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.11.009 · Cited by 1,004
Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex
Toy, D., Kugler, D., Wolfson, M., Bos, T. V., Gurgel, J., Derry, J., Tocker, J., & Peschon, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.36 · Cited by 570
Cited by
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Advances in the pathogenesis of psoriasis: from keratinocyte perspective
Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04523-3 · Cited by 632
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., & Fang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594735 · Cited by 386
Interleukin-17A and Keratinocytes in Psoriasis
Furue, M., Furue, K., Tsuji, G., & Nakahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041275 · Cited by 300
CXCL12+ dermal fibroblasts promote neutrophil recruitment and host defense by recognition of IL-17
Cavagnero, K. J., Li, F., Dokoshi, T., Nakatsuji, T., O’Neill, A. M., Aguilera, C., Liu, E., Shia, M., Osuoji, O., Hata, T., et al. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20231425 · Cited by 60
Metadata
- Authors
- Moos, S., Mohebiany, A. N., Waisman, A., & Kurschus, F. C.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 139
- Issue
- 5
- Pages
- 1110-1117
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2911246983
- Cited by
- 204
- References
- 5
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.